Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Chronic inflammatory demyelinating polyneuropathy
Economic burden and healthcare resource utilization
9 evidence topics · 9 sources
Two-year all-cause costs and resource use versus matched controls in 790 newly diagnosed US adults
“This retrospective case-control analysis was conducted using data from the IQVIA Real-World Data Adjudicated Claims.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The final sample comprised a total of 790 cases matched to 790 controls.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cases had 7.5x higher mean total costs ($116,330 vs. $15,586, p<0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Important cost drivers were costs for outpatient ancillary, radiology and HCPCS drugs (mean $76,366 vs. $4,292) and costs for inpatient care (mean $16,357 vs. $2,862) (both p<0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among cases, CIDP therapy (inclusive of both outpatient pharmacy and medical claims) accounted for 51.2% of mean total costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“From treatment initiation to the end of the 24-month follow-up, corticosteroid patients had mean (SD) CIDP therapy costs of about $7,900 ($35,000) while IVIg patients had mean CIDP therapy costs of $165,000 ($170,000).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
First-year all-cause costs by immunoglobulin use pattern in 3409 US adults
| Measure, year 1 after index | Value |
|---|---|
| All-cause outpatient visits, all patients | “31.74” |
| All-cause inpatient days, patients with at least 1 visit | “2.40” |
| Mean all-cause total cost, all patients | “$105,554” |
| Mean annual all-cause total cost, chronic immunoglobulin users | “$247,456” |
Two-year CIDP-specific costs by treatment cohort in US commercial claims
“This retrospective cohort study evaluated the treatment patterns and CIDP-related healthcare costs over a 2-year follow-up period for patients with newly diagnosed CIDP who had commercial insurance, using claims data from the IMS LifeLink PharMetrics Plus Claims database between 2009 through 2014.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean total CIDP-specific 2-year follow-up costs were highest for the cohort that received IVIG alone ($119,928) or with an additional therapy ($133,334) and lowest for patients who received active surveillance ($3723) or steroids alone ($3101).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When costs by site of care were investigated, the majority of IVIG infusion costs were found to be in the home rather than in the clinic or hospital setting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost of illness and cost drivers in the United Kingdom, France, Germany, and the United States: systematic review
“CIDP cost of illness varied across geographies, from £22,086 (2007 costs) annually per patient in the UK, through €47,823 (2017 costs) and €45,000 (2013 costs) annually per patient in France and Germany, respectively, to $116,330 (costs converted to USD 2016 values) over 2 years in the USA” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, in the US, drug-related costs represented 57% of total costs, followed by inpatient and outpatient hospital services (35%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the US, the majority of IVIG infusions occurred at home (72%), followed by physician offices (16%) and outpatient hospitals (11%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the UK, loss of productivity was estimated to cost £5815 per patient per year, and projected to cost the UK economy a total of £9.7 M per year, accounting for 26% of the total cost of illness” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Quarterly societal costs and the share attributable to immunoglobulin in 108 patients in Germany
“In total, 108 patients were recruited from 3 specialized neuroimmunological clinics.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Total quarterly costs were €11,333. Direct costs contributed to 83% of total costs (€9,423), whereas indirect costs accounted for 17% (€1,910) of total costs. The cost of intravenous immunoglobulin (IVIg) was the main determinant of total costs (67%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Reduced health-related quality of life and depressive symptoms were identified as independent predictors of higher total costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Hospitalizations, mobility aids, and productivity losses by disability level in 542 patients in five European countries
“Neurologists provided data on treatment, informal care, hospitalizations, mobility aids, and home modifications for 542 patients, while lost productivity was reported by a subset of patients ( n = 199).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hospitalizations in the 12 months prior to the survey were more frequent with greater disability (mild 7.0%, moderate 14.5%, severe 21.6%; p < 0.001), as were emergency admissions (1.0, 9.9, 13.7% respectively; p < 0.001) and ICU stays (0.0, 0.7, 3.9% respectively; p = 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The use of mobility aids (19.1, 56.1, 89.7% respectively) and home modifications (12.8, 45.8, 74.2% respectively) also rose significantly with severity ( p < 0.001 for both).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Finally, work productivity losses among employed patients and activity impairment rose as disability increased (average percentage of productivity loss: mild 21.8%, moderate 44.0%, severe: 67.3%, p < 0.001; average daily activity impairment: mild 28.6%, moderate: 44.6%, severe: 68.1%, p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As shown in Figure 4A , the proportion of patients employed at the time of the survey decreased with increasing disability severity (mild: 71.4%; moderate: 69.8%; severe: 39.1%; p = 0.049).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Annual immunoglobulin costs per person and savings from cessation trials in a UK center
“IVIg is a relatively scarce and expensive resource at a cost of £71/g, with immunomodulatory use representing £300 million per year of National Health Service (NHS) UK spending, and similar expenditure in other high income countries” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median cost of IVIg was £97 705 per person/year, at a median frequency of 2.4 days/month in the day care unit (£9213 per person/year), giving a total median cost of £106 918 per person/year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The cost saving associated with successful IVIg cessation in eight individuals was £855 344 per year, including IVIg spend and daycare unit costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Annual cost of immunoglobulin maintenance treatment by route of administration in Spain
“A cost-analysis model based on a decision tree was developed to evaluate the annual cost per patient treated with each immunoglobulin from a societal perspective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The annual cost for a patient with CIDP receiving maintenance treatment was €109,212.67 with IVIG, €98,161.97 with c-SCIG, and €98,191.37 with f-SCIG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The main driver of the difference between SCIG and IVIG cost was treatment administration (−€10,705.78).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Annual health plan paid cost per patient and share attributable to immunoglobulin in US commercial health plans, 2011
“The most prescribed therapies were intravenous immunoglobulin (IVIg) (26% of patients), gabapentin (26%), and prednisone (16%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The annual health plan paid cost was $56,953. Pharmacy cost was the major cost driver (57% of the total), and IVIg totaled 90% of the pharmacy costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote